Core Insights - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is recognized as one of the 7 cheap pharmaceutical stocks to buy according to hedge funds [1] - JP Morgan has raised the price target for AMRX by $4 while maintaining a Buy rating [2] - The company has been added to the S&P SmallCap 600 Index, which is expected to enhance its visibility to investors and improve trading liquidity [3][8] Company Developments - Amneal Pharmaceuticals focuses on developing, manufacturing, and marketing generic and specialty branded medicines across various therapeutic areas, emphasizing cost-effective access and innovation [5] - A research collaboration and option agreement was established with KeifeRx to develop KFRX06, a preclinical candidate targeting LRRK2, which is associated with Parkinson's disease [4]

Core Insights - Lantheus Holdings, Inc. (NASDAQ:LNTH) is recognized as one of the seven cheap pharmaceutical stocks to buy according to hedge funds, ranking fourth on the list [2] - TD Cowen has lowered its price target for LNTH from $80 to $75 while maintaining a Buy rating, reflecting adjustments in their financial model ahead of the company's fourth-quarter results [2][8] - The company has completed the divestiture of its Single Photon Emission Computed Tomography (SPECT) business to SHINE Technologies, which may allow it to focus on more profitable growth areas [3] Company Strategy - Lantheus is prioritizing the growth of its commercial portfolio in PET radiodiagnostics and microbubble products for contrast-enhanced ultrasound procedures [4] - The company plans to invest in and develop its pipeline of radiopharmaceuticals to support long-term growth in precision imaging and targeted treatments [4] - Lantheus aims to leverage its expertise in nuclear medicine to create innovative diagnostic and therapeutic solutions for patients [4][5]

Group 1 - Zoetis Inc. is identified as one of the cheap pharmaceutical stocks to buy according to hedge funds [1] - Bank of America raised its price target for Zoetis to $140 from $135 while maintaining a Neutral rating, supported by the company's fiscal 2026 projections and fourth-quarter performance [2] - The company reported an adjusted EPS of $1.48 for Q4 2025, exceeding the consensus forecast of $1.40, with sales increasing by 3% year-over-year to $2.4 billion [3] Group 2 - For fiscal year 2026, Zoetis projects revenue between $9.83 billion and $10.03 billion and adjusted EPS of $7.00 to $7.10, surpassing analyst forecasts [4] - The expected growth is driven by global operational gains, advancements in parasiticide and dermatology portfolios, and ongoing momentum in companion animal and cattle products [4] - Zoetis is a global leader in animal health, focusing on medicines, vaccines, and diagnostic products for livestock and companion animals [5]

Core Viewpoint - Viatris Inc. (NASDAQ:VTRS) is recognized as a promising investment opportunity among cheap pharmaceutical stocks, particularly following an upgrade from UBS, which highlights the company's growth potential and efficient capital allocation [1][3]. Group 1: Company Performance and Upgrades - UBS upgraded Viatris to a Buy rating from Neutral and increased the price target from $11 to $18, reflecting stronger growth prospects [3]. - The upgrade is attributed to Viatris' new product pipeline, ongoing cost-cutting initiatives, and rising profits, which are expected to enhance shareholder value [3][10]. Group 2: Product Launches and Innovations - Viatris launched Inpefa (sotagliflozin) in the UAE, marking the first market outside the U.S. for this treatment, with plans for additional global launches [4][5]. - Inpefa is a first-in-class dual SGLT1/2 inhibitor aimed at reducing the risk of cardiovascular death and hospitalizations in patients with heart failure, including those with type 2 diabetes or chronic renal illness [5]. - The company has submitted regulatory files in Canada, Australia, and Mexico, demonstrating its capability to implement its innovative product pipeline [6]. Group 3: Strategic Focus and Future Events - Viatris is expected to prioritize the global rollout of its products leading up to a significant Investor Event on March 19, 2026, coinciding with the release of its fourth-quarter and full-year 2025 results on February 26, 2026 [6].

Core Insights - Novartis announced positive topline results from the Phase III RemIND trial for oral remibrutinib in chronic inducible urticaria (CIndU), achieving significant complete response rates compared to placebo at Week 12 [1][2][7] - The trial met its primary endpoint across the three most prevalent types of CIndU: symptomatic dermographism, cold urticaria, and cholinergic urticaria, indicating a major advancement in treatment options for this condition [1][2][7] Company Developments - Novartis has submitted a supplemental New Drug Application (sNDA) to the FDA for remibrutinib to treat symptomatic dermographism, the most common type of CIndU [2] - The full data set from the RemIND trial will be submitted to global health authorities, and findings will be presented at upcoming medical congresses [2] Product Information - Remibrutinib is a selective oral BTK inhibitor that blocks the BTK pathway involved in histamine release, which is a key factor in hives and swelling associated with CIndU [3][7] - Currently, remibrutinib is approved in the US and China for adult patients with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines, marketed under the brand name Rhapsido [3] Clinical Trial Details - The RemIND trial is a global Phase III, multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy, safety, and tolerability of remibrutinib in adults with CIndU inadequately controlled by H1-antihistamines [4] - The primary endpoint was the proportion of complete responders at Week 12, evaluated through specific provocation tests for the three CIndU subtypes [4] Market Context - CIndU affects an estimated 0.5% of the population, equating to approximately 29 million people worldwide, and is characterized by hives triggered by identifiable external factors [5][6] - There is currently a significant unmet need for effective treatment options for CIndU, as no approved targeted therapies exist [5][6]

Equity benchmark indices Sensex and Nifty began the trade on a negative territory on Wednesday (February 18, 2026), tracking losses in IT and Services stocks in a volatile session. After a bearish start, the 30-share BSE Sensex further declined 247.92 points, or 0.30%, to 83,203.04. The 50-share NSE Nifty dropped 70.25 points, or 0.27%, to 25,655.15. Among the Sensex constituents, Infosys, Tech Mahindra, Adani Ports, HCL Technologies, Tata Consultancy Services, Eternal, Maruti Suzuki India, Asian Paints, Tr ...

Group 1 - Opko Health Inc. is considered a high-return penny stock, with a Buy rating and a price target of $3 set by H.C. Wainwright, reflecting confidence in the company's biological partnerships [1] - The subsidiary OPKO Health has expanded its collaboration with Entera Bio to develop an oral, long-acting parathyroid hormone analog for hypoparathyroidism, with positive results expected to lead to an IND filing in late 2026 [2][3] - The strategic collaboration between OPKO and Entera includes a 50% ownership interest in the LA-PTH program, with both companies sharing development costs [3] Group 2 - Opko Health operates in two main segments: diagnostics and pharmaceuticals, including BioReference Laboratories and drug development for conditions like chronic kidney disease and growth hormone deficiency [4]

Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc. (NYSE:CATX) priced an underwritten offering of 39.57 million shares at $3.78 per share. Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress The company anticipates gross proceeds of $175 million from the offering. It plans to use the net proceeds from the offering to advance the clinical development of its product candidates ...

Core Viewpoint - The company announced a class settlement agreement related to glyphosate litigation in the United States, indicating a significant step in addressing legal challenges and aligning with its broader strategic goals [1]. Group 1: Company Overview - The call featured key executives including the CEO, CFO, and Head of Litigation, highlighting the importance of the settlement and its implications for the company's future [1]. Group 2: Financial Aspects - The CFO is expected to address financial implications related to the settlement, which may impact the company's financial outlook and performance metrics [1]. Group 3: Legal Context - The Head of Litigation will provide details on the specifics of the proposed class settlement, which is crucial for understanding the legal landscape and potential future liabilities [1].

Core Viewpoint - Pfizer Inc. (PFE) has achieved a total return of 17% for investors since early November, yet caution remains regarding its future performance [1]. Group 1: Company Performance - Pfizer's stock has shown an impressive total return of 17% since early November [1]. Group 2: Analyst Perspective - The analyst expresses a neutral opinion on Pfizer despite its recent stock performance, indicating a cautious outlook [1].